Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade (CAP with NAT)

Seoul National University

Status: Completed

Conditions: Neoadjuvant Therapy; Pathological Complete Response; Pancreatic Cancer

Treatments: Drug: neoadjuvant therapy

Study type: Observational

Funder types: Other

Identifiers

NCT06630481

2407-036-1558

Details and patient eligibility

About

1. Neoadjuvant treatment (NAT) is increasingly used in managing pancreatic ductal adenocarcinoma (PDAC), necessitating dependable methods to evaluate tumor response.
2. Among various pathological tumor regression grading systems, the College of American Pathologists (CAP) system is commonly used to predict chemo-responsiveness and survival.
3. This study aimed to analyze long-term survival outcomes based on pathologic response using the CAP grade after NAT in PDAC and to identify clinicopathologic factors that influence a favorable pathologic response.

Enrollment: 462 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients (aged >18 years) who underwent pancreatic resection after NAT at a single center between January 2009 and December 2023.
• Patients were initiated on NAT after confirming PDAC diagnosis based on pathological examination.

Exclusion criteria

• Patients without a reported CAP grade
• Patients who underwent palliative surgery
• Patients who received NAT outside the specified protocol due to incomplete information.

Trial design

462 participants in 5 patient groups

CAP grade 0

Description:

No viable cancer cells in pancreatic resection specimen with neoadjuvant therapy.

Treatment:

Drug: neoadjuvant therapy

CAP grade 1

Description:

Single cells or rare small groups of cancer cells in pancreatic resection specimen with neoadjuvant therapy.

Treatment:

Drug: neoadjuvant therapy

CAP grade 2

Description:

Residual cancer with evident tumor regression in pancreatic resection specimen with neoadjuvant therapy.

Treatment:

Drug: neoadjuvant therapy

CAP grade 3

Description:

Extensive residual cancer with no evident tumor regression in pancreatic resection specimen with neoadjuvant therapy.

Treatment:

Drug: neoadjuvant therapy

pathological complete response

Description:

No viable cancer cells in pancreatic resection specimen with neoadjuvant therapy.

Treatment:

Drug: neoadjuvant therapy